Randomised controlled trials in child and adolescent health in 2023

Author:

Duke TrevorORCID

Abstract

In the year July 2022 to June 2023 there were 501 publications from randomised controlled trials (RCTs) in child and adolescent health in developing countries identified through a standardised search strategy that has been going for 20 years. This year, trials addressed the widest range of diseases and conditions that affect the health, development and well-being of children, newborns, adolescents and mothers. RCTs reflected old, neglected and new problems, the changing epidemiology of child health, social and economic circumstances in many countries, local and global priorities of low-income and middle-income countries, environmental causes of poor child health, and inequities. The RCTs tested new and refined treatments, diagnostics, vaccines, holistic management, and prevention approaches, and explored many outcomes, including mortality, nutrition, psychosocial measures, and neurodevelopment. The studies were conducted in numerous hospitals and healthcare clinics, schools, and communities, including among some of the world’s most disadvantaged populations in humanitarian and refugee emergencies. Some studies are of the highest quality, and others fall short. Many RCTs will influence guidelines, practice and policies for years to come.

Publisher

BMJ

Subject

Pediatrics, Perinatology and Child Health

Reference66 articles.

1. Typhoid conjugate vaccine effectiveness in malawi: evaluation of a test-negative design using randomised, controlled clinical trial data;Liang;Lancet Glob Health,2023

2. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial;Nampota-Nkomba;Lancet Glob Health,2022

3. Thuluva S , Paradkar V , Matur R , et al . A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's VI-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphibevTM) in healthy infants, children, and adults in comparison with a licensed comparator. Hum Vaccin Immunother 2022;18:2043103. doi:10.1080/21645515.2022.2043103

4. Vadrevu KM , Dugyala R , Mahantashetti NS , et al . Safety, immunogenicity and non-interference of concomitant typhoid VI Capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children. Hum Vaccin Immunother 2022;18:2150030. doi:10.1080/21645515.2022.2150030

5. Chaudhary S , Shah GS , Bhatta NK , et al . A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of VI-diphtheria Toxoid versus VI-tetanus Toxoid typhoid conjugate vaccine in healthy volunteers in Eastern Nepal. Hum Vaccin Immunother 2023;19:2203634. doi:10.1080/21645515.2023.2203634

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3